Applications covered include using smart RT biomaterials for boosting cancer therapy with minimal side effects, combining RT with immunotherapy or chemotherapy, reducing treatment time or health care costs, and other incipient applications.
Combining radiation with an immune system-boosting therapy called ipilimumab led to regression of metastatic tumors not targeted by the radiation in lung cancer patients, according to results of an early clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.
John, L. B., Kershaw, M. H. & Darcy, P. K. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy.
While treatment with unboosted protease inhibitors (PI) requires near perfect adherence for virologic suppression[1], the introduction of more potent non-nucleoside reverse transcriptase inhibitors (NNRTI) and ritonavir boosted PI therapy has lead to reliable virologic suppression at moderate levels of adherence for most, but not all patients[6] [9].
Our data suggest targeting TSC1/2 as a strategy for boosting antitumor immune therapy.
Current efforts focusing on gene therapy, boosting HIV-specific immunity, reducing inflammation and activation of latency have all been the subject of recent excellent reviews.
The possible negative consequences of immune system-boosting therapy are so great that we believe such an approach should be considered with great caution.
These promising hypothesis-generating studies require robust long-term control and toxicity data, but they do indicate that focal boosting (and focal salvage therapy) using mpMRI-guided HDR and LDR is a feasible method for dose escalation while minimizing OAR toxicities.
Hence, in cancer immune therapy, the boosting of IDO-specific immunity could have both direct and indirect effects (Fig. 3).
This offers the chance of boosting the initial local therapy by consecutive intravenous administrations or for interval retreatment without the necessity of craniotomy.
